Chlamydia pneumoniae, atherosclerosis and coronary heart diseases;Chlamydia pneumoniae, aterosclerosi e malattie coronariche

Italian Heart Journal, Supplementi

Volumn 4, Issue 5, 2003, Pages 383-397

  Monno, Rosa ^a   Di Biase, Matteo ^b   Costi, Antonella ^a   De Nicolò, Teresa ^b   Correale, Michele ^a   Bolognese, Pierluigi ^a   Losacco, Giandomenico ^a  

^a POLICLINICO   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Atherosclerosis; Chlamydia pneumoniae; Coronary heart disease; Myocardial infarction

Indexed keywords

ANIMAL; BACTERIAL INFECTION; CHLAMYDOPHILA PNEUMONIAE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; EPIDEMIOLOGY; HUMAN; MICROBIOLOGY; REVIEW;

ANIMALS; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; HUMANS; SEROEPIDEMIOLOGIC STUDIES;

EID: 77957118552     PISSN: 15903796     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (137)

1. Centers for Disease Control and Prevention. Achievements in public health, 1900-1999: decline in deaths from heart disease and stroke - United States, 1900-1999. Hyattsville, MD) US Department of Health and Human Services, Centers for Disease Control and Prevention, 1999: 649-56.
2. American Heart Association. 2001 Heart and stroke statistical update. Dallas, TX: American Heart Association, 2000.
3. Centers for Disease Control and Prevention. Chronic Disease Notes and Reports 1997; 10: 2-15.
4. Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998; 97: 596-601. (Pubitemid 28090690)
5. Muhlestein JB. Bacterial infections and atherosclerosis. J Investig Med 1998; 46: 396-402.
6. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
7. Davies MJ. Pathology of coronary atherosclerosis. In: Alexander RW, Schlant RC, Fuster V, eds. Hurst's the heart arteries, and veins. New York, NY: McGraw-Hill, 1998: 1161-73.
8. Clinton SK, Fleet JC, Loppnow H, et al. Interleukin-1 gene expression in rabbit vascular tissue in vivo. Am J Pathol 1991; 138: 1005-14.
9. Gaydos CA, Quinn TC. The role of Chlamydia pneumoniae in cardiovascular disease. Adv Intern Med 2000; 45: 139-73.
10. Muhlestein JB. Chronic infection and coronary artery disease. Med Clin North Am 2000; 84: 123-48.
11. Kol A, Libby P. Molecular mediators of arterial inflammation: a role for microbial products? Am Heart J 1999; 138 (Part 2): S450-S452.
12. Comandini UV, Maggi P, Santopadre P, Monno R, Angarano G, Vullo V. Chlamydia pneumoniae respiratory infections among patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 1997; 16: 720-6. (Pubitemid 27496738)
13. Monno R, De Vito D, Losito G, et al. Chlamydia pneumoniae in community-acquired pneumonia: seven years of experience. J Infect 2002; 45: 135-8. (Pubitemid 36104834)
14. Campbell LA, Kuo CC, Grayston JT. Chlamydia pneumoniae and cardiovascular disease. Emerg Infect Dis 1998; 4: 571-9.
15. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350: 430-6.
16. Karvonen M, Tuomilehto J, Pitkaniemi J, Naukkarinen A, Saikku P. Importance of smoking for Chlamydia pneumoniae seropositivity. Int J Epidemiol 1994; 23: 1315-21.
17. O'Neill C, Murray LJ, Ong GM, O'Reilly DP, Evans AE, Bamford KB. Epidemiology of Chlamydia pneumoniae infection in a randomly selected population in a developed country. Epidemiol Infect 1999; 122: 111-6. (Pubitemid 29080411)
18. Danesh J, Whincup P, Walker M, et al. Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. BMJ 2000; 321: 208-13.
19. Peeling RW, Wang SP, Grayston JT, et al. Chlamydia pneumoniae serology: interlaboratory variation in microimmunofluorescence assay results. J Infect Dis 2000; 181 (Suppl 3): S426-S429.
20. Dowell SF, Peeling RW, Boman J, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001; 33: 492-503.
21. O'Connor S. Workshop on the potential role of infectious agents in cardiovascular disease and atherosclerosis. Emerg Infect Dis 1999; 5: 186-7.
22. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983-6.
23. Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992; 116: 273-8.
24. Leinonen M, Linnanmaki E, Mattila K, et al. Circulating immune complexes containing chlamydial lipopolysaccharide in acute myocardial infarction. Microb Pathog 1990; 9: 63-73. (Pubitemid 20351285)
25. Linnanmaki E, Leinonen M, Mattila K, Nieminen MS, Valtonen V, Saikku P. Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation 1993; 87: 1130-4. (Pubitemid 23110385)
26. Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS, Daling JR. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 1992; 268: 68-72.
27. Thom DH, Wang SP, Grayston JT, et al. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arterioscler Thromb 1991; 11: 547-51.
28. Melnick SL, Shahar E, Folsom AR, et al. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am J Med 1993; 95: 449-504.
29. Puolakkinen M, Kuo CC, Shor A, Wang SP, Grayston JT, Campbell LA. Serological response to Chlamydia pneumoniae in adults with coronary arterial fatty streaks and fibrolipid plaques. J Clin Microbiol 1993; 31: 2212-4. (Pubitemid 23210523)
30. Kontula K, Vuorio A, Turtola H, Saikku P. Association of seropositivity for Chlamydia pneumoniae and coronary artery disease in heterozygous familial hypercholesterolaemia. Lancet 1999; 354: 46-7. (Pubitemid 29304307)
31. Leinonen M, Saikku P. Interaction of Chlamydia pneumoniae infection with other risk factors of atherosclerosis. Am Heart J 1999; 138 (Part 2): S504-S506. (Pubitemid 29523244)
32. Roivainen M, Viik-Kajander M, Palosuo T, et al. Infections, inflammation, and the risk of coronary heart disease. Circulation 2000; 101: 252-7. (Pubitemid 30054151)
33. Lindholt JS, Vammen S, Lind I, Fasting H, Henneberg EW. The progression of lower limb atherosclerosis is associated with IgA antibodies against Chlamydia pneumoniae. Eur J Vasc Endovasc Surg 1999; 18: 527-9. (Pubitemid 30035077)
34. Korner I, Blatz R, Wittig I, Pfeiffer D, Ruhlmann C. Serological evidence of Chlamydia pneumoniae lipopolysaccharide antibodies in atherosclerosis of various vascular regions. Vasa 1999; 28: 259-63.
35. Varveri A, Sgorbini L, Romano S, et al. Chlamydia pneumoniae infection and cardiac ischemic syndromes. Cardiologia 1998; 43: 1053-8.
36. Ossewaarde M, Feskens EJ, de Vries A, Vallinga CE, Kromhout D. Chlamydia pneumoniae is a risk factor for coronary heart disease in symptom-free elderly men, but Helicobacter pylori and cytomegalovirus are not. Epidemiol Infect 1998; 120: 93-9. (Pubitemid 28130026)
37. Grayston JT. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis 2000; 181 (Suppl 3): S402-S410. (Pubitemid 30416105)
38. Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation 1999; 99: 1161-4.
39. Ridker PM, Hennekens CH, Buring JE, Kundsin R, Shih J. Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women. Ann Intern Med 1999; 131: 573-7. (Pubitemid 29494087)
40. Miettinen H, Lehto S, Saikku P, et al. Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin-dependent diabetic and non-diabetic subjects in Finland. Eur Heart J 1996; 17: 682-8.
41. Hoffmeister A, Rothenbacher D, Wanner P, et al. Seropositivity to chlamydial lipopolysaccharide and Chlamydia pneumoniae, systemic inflammation and stable coronary artery disease: negative results of a case-control study. J Am Coll Cardiol 2000; 35: 112-8.
42. Nieto FJ, Folsom AR, Sorlie PD, Grayston JT, Wang SP, Chambless LE. Chlamydia pneumoniae infection and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 1999; 150: 149-56.
43. Colizzi C, Rizzello V, Angiolillo DJ, et al. In vitro hyperreactivity to lipopolysaccharide in patients with history of unstable angina is not associated with seropositivity for Cytomegalovirus, Helicobacter pylori and Chlamydia pneumoniae. Cardiologia 1999; 44: 377-80.
44. Coles KA, Plant AJ, Riley TV, Smith DW, McQuillan BM, Thompson PL. Lack of association between seropositivity to Chlamydia pneumoniae and carotid atherosclerosis. Am J Cardiol 1999; 84: 825-8.
45. Altman R, Rouvier J, Scazziota A, Absi RS, Gonzales C. Lack of association between prior infection with Chlamydia pneumoniae and acute or chronic coronary artery disease. Clin Cardiol 1999; 22: 85-90. (Pubitemid 29077395)
46. Nobel M, De Torrente A, Peter O, Genne D. No serological evidence of association between Chlamydia pneumoniae infection and acute coronary heart disease. Scand J Infect Dis 1999; 31: 261-4. (Pubitemid 29389233)
47. Strachan DP, Carrington D, Mendall MA, et al. Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the Caerphilly prospective heart disease study. BMJ 1999; 318: 1035-9.
48. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-7. (Pubitemid 27329411)
49. Movahed MR. Infection with Chlamydia pneumoniae and atherosclerosis: a review. J S C Med Assoc 1999; 95: 303-8.
50. von Hertzen L, Isoaho R, Kivela SL, Saikku P. Relation of Chlamydia pneumoniae antibodies to ischaemic heart disease. Finnish study finds significant association between raised IgG, but not IgA, titres and mortality. BMJ 1999; 319: 1575-6.
51. Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J 1992; 82: 158-61.
52. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993; 167: 841-9. (Pubitemid 23088253)
53. Campbell LA, O'Brien ER, Cappuccio AL, et al. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis 1995; 172: 585-8.
54. Grayston JT, Kuo CC, Coulson AS, et al. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation 1995; 92: 3397-400.
55. Kuo CC, Grayston JT, Campbell LA, Goo YA, Wissler RW, Benditt EP. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natl Acad Sci USA 1995; 92: 6911-4.
56. Ong G, Thomas BJ, Mansfield AO, Davidson BR, Taylor-Robinson D. Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications. J Clin Pathol 1996; 49: 102-6. (Pubitemid 26064914)
57. Weiss SM, Roblin PM, Gaydos CA, et al. Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy. J Infect Dis 1996; 173: 957-62.
58. Andreasen JJ, Farholt S, Jensen JS. Failure to detect Chlamydia pneumoniae in calcific and degenerative arteriosclerotic aortic valves excised during open heart surgery. APMIS 1998; 106: 717-20. (Pubitemid 28383448)
59. Apfalter P, Loidl M, Nadrchal R, et al. Isolation and continuous growth of Chlamydia pneumoniae from arterectomy specimens. Eur J Clin Microbiol Infect Dis 2000; 190: 305-8. (Pubitemid 30255615)
60. Bartels C, Maass M, Bein G, et al. Association of serology with the endovascular presence of Chlamydia pneumoniae and cytomegalovirus in coronary artery and vein graft disease. Circulation 2000; 101: 137-41. (Pubitemid 30044251)
61. Blasi F, Denti F, Erba M, et al. Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms. J Clin Microbiol 1996; 34: 2766-9. (Pubitemid 26346501)
62. Farsak B, Yildirir A, Akyon Y, et al. Detection of Chlamydia pneumoniae and Helicobacter pylori DNA in human atherosclerotic plaques by PCR. J Clin Microbiol 2000; 38: 4408-11. (Pubitemid 32244526)
63. Jantos CA, Nesseler A, Waas W, Baumgartner W, Tillmanns H, Haberbosch W. Low prevalence of Chlamydia pneumoniae in atherectomy specimens from patients with coronary heart disease. Clin Infect Dis 1999; 28: 988-92. (Pubitemid 29203526)
64. Maass M, Bartels C, Engel PM, Mamat U, Sievers HH. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 1998; 31: 827-32. (Pubitemid 28186419)
65. Siscovick DS, Schwartz SM, Corey L, et al. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults: the Cardiovascular Health Study. Circulation 2000; 102: 2335-40.
66. Wald NJ, Law MR, Morris JK, Zhou X, Wong Y, Ward ME. Chlamydia pneumoniae infection and mortality from ischaemic heart disease: large prospective study. BMJ 2000; 321: 204-7. (Pubitemid 30459556)
67. Johnson WD, Moses J, Kipshidze N. Absence of Chlamydia pneumoniae in surgical specimens of coronary and carotid arteries by polymerase chain reaction. Cardiovasc Radiat Med 2001; 2: 221-4. (Pubitemid 34838880)
68. Hoymans V, Bosmans J, Ursi D, et al. Systemic inflammation, Chlamydia pneumoniae DNA in circulating leukocytes and coronary atherosclerosis. Acta Cardiol 2002; 57: 213-9.
69. Ngeh J, Gupta S. Chlamydia pneumoniae and atherosclerosis: causal or coincidental link? ASM News 2000; 66: 732-7.
70. Benson RL, Smith KG, Semenov H. Experimental arteritis and arteriosclerosis associated with streptococcal inoculations. Arch Pathol 1931; 12: 924-40.
71. Fabricant CG, Krook L, Gillespie JH. Virus-induced cholesterol crystals. Science 1973; 181: 566-7.
72. Fong IW, Chiu B, Viira E, Fong MW, Jang D, Mahony J. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol 1997; 35: 48-52. (Pubitemid 26422626)
73. Campbell LA, Rosenfeld M, Kuo CC. The role of Chlamydia pneumoniae and atherosclerosis - recent evidence from animal models. Trends Microbiol 2000; 8: 255-7. (Pubitemid 30330990)
74. Laitinen K, Laurila A, Pyhala L, Leinonen M, Saikku P. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immun 1997; 65: 4832-5. (Pubitemid 27463264)
75. Hu H, Pierce GN, Zhong G. The atherogenic effects of Chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999; 103: 747-53. (Pubitemid 29122429)
76. Campbell LA, Kuo CC. Mouse models of Chlamydia pneumoniae infection and atherosclerosis. Am Heart J 1999; 138 (Part 2): S516-S518. (Pubitemid 29523248)
77. Campbell LA, Moazed TC, Kuo CC, Grayston JT. Preclinical models for Chlamydia pneumoniae and cardiovascular disease: hypercholesterolemic mice. Clin Microbiol Infect 1998; 4 (Suppl 4): S23-S32.
78. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97: 633-6.
79. Rothstein NM, Quinn TC, Madico G, Gaydos CA, Lowenstein CJ. Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae. J Infect Dis 2001; 183: 232-8. (Pubitemid 32066024)
80. Tambiah J, Franklin IJ, Trendell-Smith N, Peston D, Powell JT. Provocation of experimental aortic inflammation and dilatation by inflammatory mediators and Chlamydia pneumoniae. Br J Surg 2001; 88: 935-40. (Pubitemid 34015574)
81. Tambiah J, Powell JT. Chlamydia pneumoniae antigens cause experimental aortic dilatation: an effect counteracted by azithromycin. Br J Surg 2001; 88 (Suppl 1): 3.
82. Aalto-Setala K, Laitinen K, Erkkila L, et al. Chlamydia pneumoniae does not increase atherosclerosis in the aortic root of apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21: 578-84.
83. Caligiuri G, Rottenberg M, Nicoletti A, Wigzell H, Hansson GK. Chlamydia pneumoniae infection does not induce or modify atherosclerosis in mice. Circulation 2001; 103: 2834-8. (Pubitemid 32550073)
84. Blessing E, Campbell LA, Rosenfeld ME, Kuo CC. Chlamydia pneumoniae and hyperlipidemia are co-risk factors for atherosclerosis: infection prior to induction of hyperlipidemia does not accelerate development of atherosclerotic lesions in C57BL/6J mice. Infect Immun 2002; 70: 5332-4.
85. Moazed TC, Campbell LA, Rosenfeld ME, Grayston JT, Kuo CC. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J Infect Dis 1999; 180: 238-41.
86. Fong IW, Chiu B, Viira E, Jang D, Mahony JB. Influence of chlarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model. Antimicrob Agents Chemother 2002; 46: 2321-6. (Pubitemid 34793430)
87. Muhlestein JB, Anderson JL, Carlquist JF, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 2000; 102: 1755-60.
88. Jackson LA, Stewart DK, Wang SP, Cooke DB, Cantrell T, Grayston JT. Safety and effect on anti-Chlamydia pneumoniae antibody titres of a 1 month course of daily azithromycin in adults with coronary artery disease. J Antimicrob Chemother 1999; 44: 411-4. (Pubitemid 29425697)
89. Sinisalo J, Mattila K, Nieminen M, et al. The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factors and forearm basal nitric oxide production. J Antimicrob Chemother 1998; 41: 85-92.
90. Torgano G, Cosentini R, Mandelli C, et al. Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. Circulation 1999; 99: 1555-9.
91. Semaan HB, Gurbel PA, Anderson JL, et al. The effect of chronic azithromycin therapy on soluble endothelium-derived adhesion molecules in patients with coronary artery disease. J Cardiovasc Pharmacol 2000; 36: 533-7.
92. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet 1997; 350: 404-7. (Pubitemid 27331235)
93. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J 1999; 20: 121-7.
94. Melissano G, Blasi F, Esposito G, et al. Chlamydia pneumoniae eradication from carotid plaques. Results of an open, randomised treatment study. Eur J Vasc Endovasc Surg 1999; 18: 355-9.
95. Meier CR, Derby LE, Jick SS, Vasilakis C, Jick H. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 1999; 281: 427-31. (Pubitemid 29069440)
96. Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM. Past use of erythromycin, tetracycline, or doxycycline is not associated with risk of first myocardial infarction. J Infect Dis 2000; 181 (Suppl 3): S563-S565.
97. Anderson JL, Muhlestein JB, Carlquist JF, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999; 99: 1540-7.
98. Neumann F, Kastrati A, Miethke T, et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet 2001; 357: 2085-9. (Pubitemid 32607452)
99. Dunne MW. Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD [weekly intervention with zithromax (azithromycin) for atherosclerosis and its related disorders] trial. J Infect Dis 2000; 181 (Suppl 3): S572-S578.
100. Gupta S. Chlamydia pneumoniae, monocyte activation, and azithromycin in coronary heart disease. Am Heart J 1999; 138 (Part 2): S539-S541. (Pubitemid 29523254)
101. Jackson LA. Description and status of the azithromycin and coronary events study (ACES). J Infect Dis 2000; 181 (Suppl 3): S579-S581.
102. Vergassola R, Mazzoli S, Pazzagli L, et al. Chlamydia pneumoniae and myocardial infarction (CLAINF). Preliminary randomized controlled study with clarithromycin. CLAINF protocol. Minerva Cardioangiol 2000; 48: 411-25.
103. Anand V, Gupta S. Antibiotic therapy in coronary heart disease - where do we currently stand? Cardiovasc Drugs Ther 2001; 15: 209-10.
104. Gupta S, Kaski JC. Infections and coronary heart disease: potential for new therapy? In: Betteridge J, ed. Lipids: current perspectives. Vol 2. London: Martin Dunitz, 2000.
105. Stone AF, Mendall MA, Kaski JC, et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 2002; 106: 1219-23.
106. Gay K, Baughman W, Miller Y, et al. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment. J Infect Dis 2000; 182: 1417-24.
107. Scaglione F, Rossoni G. Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J Antimicrob Chemother 1998; 41 (Suppl B): 47-50. (Pubitemid 28152223)
108. Uriarte SM, Molestina RE, Miller RD, et al. Effect of macrolide antibiotics on human endothelial cells activated by Chlamydia pneumoniae infection and tumor necrosis factor-alpha. J Infect Dis 2002; 185: 1631-6.
109. Kuvin JT, Kimmelstiel CD. Infectious causes of atherosclerosis. Am Heart J 1999; 137: 216-26.
110. Kaukoranta-Tolvanen SS, Laitinen K, Saikku P, Leinonen M. Chlamydia pneumoniae multiplies in human endothelial cells in vitro. Microb Pathog 1994; 16: 313-9. (Pubitemid 24253076)
111. Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn TC. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun 1996; 64: 1614-20.
112. Knoebel E, Vijayagopal P, Figueroa JE II, Martin DH. In vitro infection of smooth muscle cells by Chlamydia pneumoniae. Infect Immun 1997; 65: 503-6.
113. Kaul R, Wenman WM. Chlamydia pneumoniae facilitates monocyte adhesion to endothelial and smooth muscle cells. Microb Pathog 2001; 30: 149-55. (Pubitemid 32552996)
114. Kaukorata-Tolvanen SS, Teppo AM, Laitinen K, Saikku P, Linnavuori K, Leinonen M. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb Pathog 1996; 21: 215-21. (Pubitemid 26290572)
115. Hwang S-J, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1997; 96: 4219-25.
116. Nishiyama K, Ogawa H, Yasue H, et al. Simultaneous elevation of the levels of circulating monocyte chemoattractant protein-1 and tissue factor in acute coronary syndromes. Jpn Circ J 1998; 62: 710-2.
117. Ridker PM, Rifai N, Stampfer M, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-72. (Pubitemid 30213096)
118. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149-53. (Pubitemid 30253042)
119. Fryer RH, Schwobe EP, Woods ML, Rodgers GM. Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J Investig Med 1997; 45: 168-74.
120. Schumacher A, Seljeflot I, Lerkerod AB, Sommervoll L, Otterstad JE, Arnesen H. Positive Chlamydia pneumoniae serology is associated with elevated levels of tumor necrosis factor alpha in patients with coronary heart disease. Atherosclerosis 2002; 164: 153-60. (Pubitemid 34765647)
121. Kohara K, Tabara Y, Yamamoto Y, Igase M, Miki T. Chlamydia pneumoniae seropositivity is associated with increased plasma levels of soluble cellular adhesion molecules in community-dwelling subjects: the Shimanami Health Promoting Program (J-SHIPP) study. Stroke 2002; 33: 1474-9. (Pubitemid 34619942)
122. Lopes-Virella MF. Interactions between bacterial lipopolysaccharides and serum lipoproteins and their possible role in coronary heart disease. Eur Heart J 1993; 14 (Suppl K): 118-24.
123. Koenig W. Atherosclerosis involves more than just lipids: focus on inflammation. Eur Heart J 1999; 1 (Suppl): 19-26.
124. Molestina RE, Miller RD, Ramirez JA, Summersgill JT. Infection of human endothelial cells with Chlamydia pneumoniae stimulates transendothelial migration of neutrophils and monocytes. Infect Immun 1999; 67: 1323-30.
125. Palinski W, Rosenfeld ME, Yla-Herttuaala S, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989; 86: 1372-6. (Pubitemid 19061548)
126. Kalayoglu MV, Byrne GI. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis 1998; 177: 725-9.
127. Kol A, Bourcier T, Lichtman AH, Libby P. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest 1999; 103: 571-7. (Pubitemid 29094058)
128. Schussheim AE, Fuster V. Antibiotics for myocardial infarction? A possible role of infection in atherogenesis and acute coronary syndromes. Drugs 1999; 57: 283-91. (Pubitemid 29137476)
129. Rodel J, Woytas M, Groh A, et al. Production of basic fibroblast growth factor and interleukin 6 by human smooth muscle cells following infection with Chlamydia pneumoniae. Infect Immun 2000; 68: 3635-41. (Pubitemid 30340468)
130. Sasu S, LaVerda D, Qureshi N, Golenbock DT, Beasley D. Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ Res 2001; 89: 244-50. (Pubitemid 34132682)
131. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 1998; 98: 300-7. (Pubitemid 28348051)
132. Dechend R, Maass M, Gieffers J, et al. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis. Circulation 1999; 100: 1369-73. (Pubitemid 29451694)
133. Molestina RE, Miller RD, Lentsch AB, Ramirez JA, Summersgill JT. Requirement for NF-kappaB in transcriptional activation of monocyte chemotactic protein 1 by Chlamydia pneumoniae in human endothelial cells. Infect Immun 2000; 68: 4282-8.
134. Tiran A, Gruber HJ, Graier WF, Wagner AH, Van Leeuwen EB, Tiran B. Aspirin inhibits Chlamydia pneumoniae-induced nuclear factor-kappa B activation, cytokine expression, and bacteria development in human endothelial cells. Arterioscler Thromb Vasc Biol 2002; 22: 1075-80. (Pubitemid 34764855)
135. Miller SA, Selzman CH, Shames BD, Barton HA, Johnson SM, Harken AH. Chlamydia pneumoniae activates nuclear factor kB and activator protein 1 in human vascular smooth muscle and induces cellular proliferation. J Surg Res 2000; 90: 76-81.
136. Leinonen M. Pathogenetic mechanisms and epidemiology of Chlamydia pneumoniae. Eur Heart J 1993; 14 (Suppl K): 57-61. (Pubitemid 24038955)
137. Xu Q, Willeit J, Marosi M, et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 1993; 341: 255-9.